Gene testing for thalassemia
Gene testing for thalassemia

Gene testing for thalassemia

Brief introduction

  Thalassemia is one of the most common and harmful↓→ ε single-gene genetic diseases in the •✔↕&world, anemia or pathological state caused by ≥↔£the lack or deficien↔✘cy of one or more globgenin strains in σ♠↕→hemoglobin due to genetic beglop׶¶ er gene defects. Name and classify the t​&γσype and degree of glober chain defici'§$ency. According to the severity of ★σ↕the disease, divided into heπ↑≤αavy, intermediate, light threφ↔≈§e types, heavy: 3-6γα≥π months after birth s​↓↑ymptoms, often die in chi π≤ldhood;

    The disease is ελγwidely distributed in many parts of th£≥↔♥e world, black areas of the United St•"$ates, Southeast Asia, the Indian•₽ subcontinent and southern China: Guan↔α$₽gdong, Guangxi, Yunnan, Hainan and oth→•er places for high-risk areaπ ≤ s, the population carrying rate of up to 2₽​♥4%. At least 350 mil™ ♠Ωlion people worldwide carry the teΩ<♥rrestrial poverty gene.


Yiligang Launches More €πComprehensive Gene Tes$&↕ting Program
Missing α-thalassemia gene det"ε•ection kit
4 types were tested at one time, and the Thai"Ω☆ type with relatively high incid♦≥ence in Guangxi District was teste∑™≈d to prevent leaks more comprehensively. B‌‍ecause China is a country with a large p•₽opulation flow, it is also necessary to® ‌∏ test in other regions.
 
Non-deletion α-thalassemi↕σa gene detection kit
Detection of three types and®α↕γ missing alpha and beta thalas←©semias at one time forms the most comprehe ♦ ®nsive product on the market.
 
β-thalassemia gene mutation detection kit
Detecting 19 types at a time. Comp☆¶δared with other CFDA products, it exclus↔£ively tests -50M, which has a higher mutatio ✔n frequency, to prevent leaks÷ •∑ more comprehensivelΩ§"y. Because China is a country with a large £©←population flow, it is also neces₹®γsary to test in other regions.¥π
 
※ Each additional new"♥÷ genotype is the result of a ✔∑₽≤large rheological data assessment. The mutation o "÷↑f each genotype is only a pro£₩‌>bability of occurrence ☆©§ for the general public, but for the occurrence, ®₽πit is related to the happiness of t₽✔↔he entire family! So we all take it seriou≠π↕'sly!
Product advantages

Comprehensive coverage: more comprehensive coβ♣verage of the incidence site detec♥γ≈tion, for each region to carry higher gene mutant‍₹ type supplement, is currently a hot gene s∏✘₩∑election more comprehen∏"δ↑sive CFDA registered pr★≈£oducts, greatly redu≤ε"cing the risk of missed detection;
High accuracy: detection of known missing types of ♥φλsamples, the results show the corresponding missiφ₩₹ng type, accuracy is m π↔✘ore than 99%;
High specificity: detection of non-poor human genom♣€e DNA samples, specifictocoming" §♥ more than 99%;
Technology reliability: technology platform after many years oΩ€€λf clinical and the vast number of hos☆←pitals recognized and verified;
Applicability:  The conditions of use are £§‍∞simple and can be carried out ♣€∏in a normal PCR laboratory. 

Product information and perf &ormance

Product name

Missing alpha-thalassemia gene te↑εst kit

Non-missing alpha-thalassemia 

gene testkit

Beta-thalassemia gene 

mutation test kit

Detection method

Gap-PCR Law

PCR-reverse point hybridization

Sample requirements

Anticoagulant whole blood or genomic ©↓DNA

Application instruments

Gene amplification instrument, electrophoresis

Gene amplification instrument, molecu♦π‍lar hybridizer

Packaging specifications

25 tests/kit

High accuracy

Positive and negative compliance rat≤₹δes are up to 100%

High sensitivity

Stable detection of genomic DNA sampl<​₹'es with a concentration of 2 ng/sL↔π

Precision

In-batch and inter-batc§←h products using standard genomi∏​φ​c 

DNA testing for precision referencβ✔e concentrations of 10ng/μL

Easy to operate 

time-saving

After amplification, you can produce resul®₩ts 

with simple electrophoresis

Both can be used for PCR, hybrid, 

color display at the same time

Repeatability

100% consistency

Genetic law
Suitable for the crowd

Causes of thalassemia;
Thalassaemia risk assess×'εment of childcare before pregnancy;
Blocking of children with thalassaemia during pr↔λegnancy;
High-risk groups, newborn screδ÷σening.